Blog of Signaling Pathways
May 22 2013
In vitro characterization of the erythrocyte distribution of methazolamide: a model of erythrocyte transport and binding kinetics
>Read the Full Post
( 0 )Comments |
( 12 )Read
May 20 2013
Rucaparib also reduces the migration of some cancer and normal cells in culture.It can be taken orally in tablet form.
>Read the Full Post
( 0 )Comments |
( 15 )Read
May 16 2013
Motesanib Diphosphate has broad activity against the human VEGFR family, and displays >1000 selectivity against EGFR, Src, and p38 kinase.
>Read the Full Post
( 0 )Comments |
( 21 )Read
May 14 2013
It is well understood that the classical mechanism of action of ouabain involves its binding to and inhibition of the plasma membrane Na+/K+-ATPase (sodium pump) especially at the higher concentrations attainable in vitro or with intravenous dosage.
>Read the Full Post
( 0 )Comments |
( 30 )Read
May 10 2013
MK-801 has a great deal of potential to be used in research in creating animal models of schizophrenia. Unlike dopaminergic agonists, which mimic only the positive symptoms of schizophrenia, a single injection of MK801 was successful in modelling both the positive and negative symptoms of schizophrenia.
>Read the Full Post
( 0 )Comments |
( 35 )Read
May 08 2013
AZD6244 also inhibits the growth of primary HCC cells through inhibition of ERK1/2 and p90RSK phosphorylation, accompanied with elevation of the cleavage of caspase-3 and caspase-7, and cleaved poly(ADP)ribose polymerase.
>Read the Full Post
( 0 )Comments |
( 42 )Read
May 06 2013
Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a US National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol. Later it was discovered that endophytic fungi in the bark synthesize paclitaxel.
>Read the Full Post
( 0 )Comments |
( 34 )Read
May 02 2013
LY2484595 results in 98.4%, 98.6%, and 18.4% inhibition of CETP activity at 4 hours, 8 hours and 24 hours post dose respectively in human ApoAI and CETP double transgenic mice.
>Read the Full Post
( 0 )Comments |
( 41 )Read
Apr 28 2013
Tubastatin A is substantially selective for all 11 HDAC isoforms and maintains over 1000-fold selectivity against all isoforms excluding HDAC8, where it has approximately 57-fold selectivity.
>Read the Full Post
( 0 )Comments |
( 71 )Read
Apr 26 2013
SP600125 is originally characterized as a selective ATP-competitive inhibitor of c-Jun N-terminal kinase JNK. In Jurkat T cells, SP600125 inhibits the phosphorylation of c-Jun with IC50 of 5 μM to 10 μM.
>Read the Full Post
( 0 )Comments |
( 60 )Read
